GIP and Obesity: Treatments that regulate metabolism, particularly gastrointestinal hormones, are becoming increasingly common; for example, GIP plus glucagon or a triagonist comprising GIP, GLP-1 and glucagon is also being developed for patients with obesity, diabetes or dyslipidaemia.